Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Amorepacific Corporation
  6. News
  7. Summary
    A090430   KR7090430000

AMOREPACIFIC CORPORATION

(A090430)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Amorepacific : Confirms the Effect of Moisturizer Tailored for Chemotherapy Patients

12/02/2021 | 02:41am EST
Amorepacific Confirms the Effect of Moisturizer Tailored for Chemotherapy Patients R&D2021-11-30
  • Improvement in dry skin of chemotherapy patients through join research with Samsung Medical Center
  • Research result published in the latest issue of the Journal of the American Academy of Dermatology, internationally renowned in the dermatology field

The result of joint research by Amorepacific and Samsung Medical Center has been published in an internationally prestigious journal of dermatology.

Amorepacific has been jointly researching changes in skin and hair after chemotherapy with Samsung Medical Center for 10 years as of this year. The company has developed a product that eases dry skin of chemotherapy patients and analyzed the effect of the tailored moisturizer. The details were introduced in the latest issue of the Journal of the American Academy of Dermatology (IF 11.527).

Many patients undergoing chemotherapy complain of dry and itchy skin as a symptom. They struggle with the symptom as it cannot be eased with ordinary moisturizers. In 2014, a research team led by Professors Ahn Jin-seok Ahn, Jo Joo-hee, and Kang Dan-bi of Samsung Medical Center found the cause of dryness and itchiness and identified the need for a customized moisturizer for the patients. The joint research team developed a tailored moisturizing product containing high-content ceramide and conducted clinical trials. As a result, the team confirmed that the new product can alleviate dry symptoms that cannot not be eased with regular moisturizers and published related paper. primera, Amorepacific's mindful and clean beauty brand, had previously launched a product that applied the high-content ceramide prescription used in the study.

Park Young-ho, head of Amorepacific's R&D Center, says, "Amorepacific is researching the changes in skin and hair experienced during chemotherapy and developing products necessary for patients who are suffering from treatment. We hope that the result of this joint research will also help cancer patients improve their quality of life."

Disclaimer

Amorepacific Corporation published this content on 30 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 December 2021 07:40:03 UTC.


ę Publicnow 2021
All news about AMOREPACIFIC CORPORATION
2021AMOREPACIFIC CORPORATION : Ex-dividend day for final dividend
FA
2021AMOREPACIFIC : Signs MOU on Renewable Energy Supply with SK E&S for Carbon Neutrality
PU
2021AMOREPACIFIC : Confirms the Effect of Moisturizer Tailored for Chemotherapy Patients
PU
2021AMOREPACIFIC : Leads K-Beauty Craze at BTS US Concert
PU
2021AMOREPACIFIC : Enters Global MOU for Sustainable Packaging with Eastman
PU
2021AMOREPACIFIC : Launches Product in Collaboration with BTS
PU
2021AMOREPACIFIC : ‘BeREADY' Donates Equipment for Mountain Rescuers
PU
2021AMOREPACIFIC : Concludes ‘2021 Love the Earth Eco Influencer Course'
PU
2021Amorepacific Introduces Special Collaboration with BTS
CI
2021AMOREPACIFIC : Wins Mécénat Award 2021
PU
More news
Financials
Sales 2021 4 783 B 4,02 B 4,02 B
Net income 2021 261 B 0,22 B 0,22 B
Net cash 2021 935 B 0,79 B 0,79 B
P/E ratio 2021 32,8x
Yield 2021 0,68%
Capitalization 9 453 B 7 932 M 7 940 M
EV / Sales 2021 1,78x
EV / Sales 2022 1,54x
Nbr of Employees 5 088
Free-Float 55,2%
Chart AMOREPACIFIC CORPORATION
Duration : Period :
Amorepacific Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMOREPACIFIC CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 149 500,00 KRW
Average target price 226 360,00 KRW
Spread / Average Target 51,4%
EPS Revisions
Managers and Directors
Kyung-Bae Suh Chairman & Co-Chief Executive Officer
Se-Hong Ahn Co-Chief Executive Officer & Director
O-Bin Kwon Managing Director & MD-Finance
Jin-Woo Kim MD & MD-Information Technology Division
Jin-Bong Kim Head-Compliance Support
Sector and Competitors
1st jan.Capi. (M$)
AMOREPACIFIC CORPORATION-10.48%7 932
L'ORÉAL-7.60%245 087
KAO CORPORATION-4.72%23 718
SHISEIDO COMPANY, LIMITED-9.79%20 172
DCC PLC3.70%8 450
COTY INC.-14.95%7 488